CRISPR THERAPEUTICS AG (NASDAQ:CRSP) Files An 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal YearItem 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
As previously reported, at the 2017 Annual General Meeting of Shareholders of the Company, the Company’s shareholders approved amendments to its Articles of Association to increase the Company’s conditional share capital for employee benefit plans and to change the Company’s registered office from Basel, Switzerland to Zug, Switzerland. The Company’s amended and restated Articles of Association became effective upon registration in the Commercial Register in the canton of Zug, Switzerland on July18, 2017. A copy of the amended and restated Articles of Association is attached hereto as Exhibit 3.1 and incorporated herein by reference.
Item 5.03.Financial Statements and Exhibits.
(d)Exhibits:
|
ExhibitNo. |
Description |
| 3.1 | Amended and Restated Articles of Association of CRISPR Therapeutics AG, dated May31, 2017 |
CRISPR Therapeutics AG ExhibitEX-3.1 2 d419003dex31.htm EX-3.1 EX-3.1 Exhibit 3.1 ARTICLES OF ASSOCIATION of CRISPR Therapeutics AG (CRISPR Therapeutics SA) (CRISPR Therapeutics Ltd) with registered office in Zug (Translation; in case of controversy the German text shall prevail) STATUTEN der CRISPR Therapeutics AG (CRISPR Therapeutics SA) (CRISPR Therapeutics Ltd) mit Sitz in Zug I. CORPORATE NAME,…To view the full exhibit click here
About CRISPR THERAPEUTICS AG (NASDAQ:CRSP)
Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell. The location at which the Cas9 molecular scissors cut the DNA to be edited is specified by guide ribonucleic acid (RNA), which is comprised of a crRNA component and a tracrRNA component, either individually or combined together as a single guide RNA. The Company has business operations in London, the United Kingdom, as well as research and development operations in Cambridge, the United States.